Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 95.5% from a year ago
Total equity stood at $167.62M at the end of Q1 FY2026, up 95.5% from a year earlier and down 3.1% from the prior quarter. Over 3 fiscal years it compounded at +101.8% a year.
Context
- Total equity amounted to 96.7% of total assets at the end of Q1 FY2026, up 5.8 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +95.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 172.9M USD
- Year-over-year change
- +82.3%
- 4-year CAGR
- +45.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 172.9M | +82.3% |
| FY2024 | 2024-12-31 | 94.87M | +764.2% |
| FY2023 | 2023-12-31 | 10.98M | -47.8% |
| FY2022 | 2022-12-31 | 21.04M | -45.2% |
| FY2021 | 2021-12-31 | 38.42M | — |
Total Equity vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's Mar 2026 total equity of $167.62M is the highest of the 8 companies compared; the peer median is $5.27M.
- Its year-over-year change of +95.5% is the 3rd highest of 7, against a peer median of -7.8%.
- Total equity amounts to 96.7% of total assets for IKT, versus a peer median of 81.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $167.62M | +95.5% | +101.8% | 96.7% | |
| Mar 2026 | $29.91M | +143.8% | -5.2% | 82.8% | |
| Mar 2026 | $10.69M | -44.9% | +3.7% | 81.4% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $6.12M | — | — | 32.8% |
| Mar 2026 | $5.27M | +301.6% | -48.6% | 50.2% | |
EXOZeXoZymes, Inc. | Mar 2026 | $1.53M | -82.8% | +35.3% | 38.0% |
| Mar 2026 | -$227.98M | +29.3% | — | 122.3% | |
| Mar 2026 | -$278.15M | -5002.1% | — | 230.4% | |
| Peer median (excluding IKT) | $5.27M | -7.8% | -0.8% | 81.4% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 40.75M | 7.19M | 9.17M | 56.49M | 139.22M |
| Short-term Investments | 0 | 15.86M | 4.09M | 41.05M | 39.54M |
| Net Receivables | 110.14K | 39.88K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 107K | 1.12M | 739.18K | 106.31K | 343.37K |
| Total Current Assets | 42.47M | 24.37M | 14.21M | 98.45M | 180.11M |
| Property, Plant & Equipment (Net) | 0 | 565.18K | 295.6K | 148.54K | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 1.1M |
| Total Non-current Assets | 0 | 565.18K | 295.6K | 148.54K | 1.1M |
| Total Assets | 42.47M | 24.94M | 14.51M | 98.6M | 181.2M |
| Account Payables | 1.09M | 1.15M | 646.77K | 943.02K | 1.16M |
| Short-term Debt | 248.91K | 0 | 381.78K | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 635.45K | 0 | 6.32M |
| Total Current Liabilities | 4.05M | 3.7M | 3.44M | 3.73M | 8.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 205.45K | 90.12K | 0 | 0 |
| Total Liabilities | 4.05M | 3.9M | 3.53M | 3.73M | 8.3M |
| Common Stock | 25.16K | 4.22K | 6.19K | 69.36K | 131.69K |
| Retained Earnings | (29.82M) | (47.87M) | (66.9M) | (94.42M) | (142.68M) |
| Accumulated OCI | 0 | 104.72K | 877 | (37.25K) | 21.8K |
| Other Stockholders Equity | 0 | 0 | 0 | 777 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 38.42M | 21.04M | 10.98M | 94.87M | 172.9M |
| Total Debt | 248.91K | 351.29K | 622K | 110.52K | 0 |
| Net Debt | (40.5M) | (6.84M) | (8.54M) | (56.38M) | (139.22M) |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.